Gold prices edge higher on raised Fed rate cut hopes
Director William H. Carson purchased 4,115 shares of Annexon Inc . (NASDAQ:ANNX) on July 30, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at a weighted average price of $2.43, in a range from $2.37 to $2.44, resulting in a total transaction value of $9,999. The purchase comes as InvestingPro analysis shows the stock trading below its Fair Value, with analysts maintaining a strong buy consensus and a significantly higher price target.
Following the transaction, Carson directly owns 33,830 shares of Annexon. The company maintains a strong liquidity position with a current ratio of 7.99 and more cash than debt on its balance sheet, though InvestingPro data indicates rapid cash burn remains a concern.
The purchase was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2025. The stock has shown strong momentum over the past three months, despite being down about 60% over the past year. Subscribers to InvestingPro can access 7 additional key insights about Annexon’s financial health and market position.
In other recent news, Annexon, Inc. has completed enrollment for its Phase 3 ARCHER II trial of vonaprument, a treatment for dry age-related macular degeneration with geographic atrophy. The trial exceeded its target of 630 participants, and topline data is anticipated in the latter half of 2026. Additionally, Annexon has amended its 2022 warrants, extending the term by one year to June 30, 2026, and limiting the exercise to cash transactions at a price of $5.806875 per share. In a separate development, the company reported promising results for its investigational therapy, tanruprubart, in treating Guillain-Barré Syndrome. At the Peripheral Nerve Society Annual Meeting, findings indicated that patients treated with tanruprubart experienced a rapid and sustained recovery. Furthermore, Cantor Fitzgerald has maintained its Overweight rating on Annexon, citing the potential for stock appreciation if ANX005 is approved for Guillain-Barré Syndrome. The firm also noted Annexon’s solid financial position, with approximately $264 million in cash.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.